NFH
ADAP

NEXT Financial Holdings’s Adaptimmune Therapeutics ADAP Stock Holding History

NEXT Financial Holdings’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$2K Buy
+475
New +$2.21K ﹤0.01% 1423

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NEXT Financial Holdings's ADAP Position: Q1 2019 in Review

NEXT Financial Holdings opened a new position in Adaptimmune Therapeutics (ADAP) in Q1 2019: 475 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #1423 among its holdings.

68 funds tracked by Wall St. Rank hold ADAP as of Q1 2019.

  • NEXT Financial Holdings held 475 shares of Adaptimmune Therapeutics worth $2K as of Q1 2019.
  • Adaptimmune Therapeutics was a new NEXT Financial Holdings position in Q1 2019.
  • Adaptimmune Therapeutics made up ﹤0.01% of NEXT Financial Holdings's portfolio in Q1 2019, its #1423 holding.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2019.

Based on NEXT Financial Holdings's 13F filing for Q1 2019, filed 13 May 2019.